Testing iadademstat plus gilteritinib for relapsed AML with FLT3 mutation
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 1 study tests whether a new drug called iadademstat, combined with gilteritinib, can help people with relapsed or refractory AML that has certain FLT3 mutations. It’s mainly looking to find a safe dose and see early signs of effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have AML (or AML with myelodysplasia-related changes, called AML-MRC) proven by a pathology report.
- Your leukemia is in 1st or 2nd relapse, or it is refractory (not responding), and it has not had more than 2 prior treatment lines for AML.
- Your leukemia tests positive for specific FLT3 mutations (FLT3-ITD and/or FLT3-TKD types like D835 or I836).
- You are well enough for study treatment (ECOG 0–2) and your doctor expects you could live at least 3 months.
- Your liver and kidneys are working well enough for treatment, and you can swallow pills.
- Your current medication history fits the rules (no prior iadademstat; certain other prior drugs/investigational treatments are allowed only in specific situations).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests how well gilteritinib works when combined with either ivosidenib or enasidenib in adults with relapsed or refractory acute myeloid leukemia (AML). It targets specific genetic changes in the leukemia and may help shrink or control the cancer when standard options haven’t worked.
This trial tests if adding the targeted drug gilteritinib to standard chemotherapy improves outcomes for adults with a specific type of AML (FLT3-ITD+). It's for newly diagnosed patients who can tolerate intensive treatment.
This trial tests a new combination of chemotherapy (FLAI) and a targeted drug (Gilteritinib) for adults with acute myeloid leukemia (AML) that has a specific genetic change called FLT3. It aims to see if the combo works better than standard treatment.
This trial tests a combination of three medicines—azacitidine, venetoclax, and gilteritinib—in people with specific gene changes (FLT3 mutations) in leukemia and related bone marrow diseases that have come back or are hard to treat. The goal is to see if this drug combination can control the disease and improve outcomes.
This trial tests whether adding an oral chemotherapy pill (azacitidine) to the targeted drug gilteritinib helps people whose FLT3-mutated AML came back or didn't respond after their first treatment. The goal is to see if the combination is more effective than gilteritinib alone.
This trial tests a combination of two targeted drugs, SNDX-5613 and gilteritinib, for people whose AML has come back or hasn't responded to treatment. It is for those with an FLT3 gene mutation plus another specific genetic change like NPM1 or MLL. The study aims to see if this two-drug approach works better when used together.
Hear when a new Acute Myeloid Leukemia, in Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.